Metraipolis › archive › dc_c89837910a36
Pan-tumor validation of FoundationOne®CDx as a companion diagnostic for RET fusions as a predictor of response to selpercatinib — Europe PMC PMID:42211499
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42211499
- DOI
- 10.3389/fonc.2026.1820286
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T07:25:08.818Z
- SHA-256 of the archived text
5930039d62ca7853af18a676d8770ae5f34437a2d882c27187df3dc65dbf82a5- Stable URL of this page
https://metraipolis.com/documento/dc_c89837910a36
How to cite
Pan-tumor validation of FoundationOne®CDx as a companion diagnostic for RET fusions as a predictor of response to selpercatinib — Europe PMC PMID:42211499 — Europe PMC (en), https://europepmc.org/article/MED/42211499 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c89837910a36 (Metraipolis archive dc_c89837910a36, sha256 5930039d62ca7853af18a676d8770ae5f34437a2d882c27187df3dc65dbf82a5)
BibTeX
@misc{dcc89837910a36,
title = {Pan-tumor validation of FoundationOne®CDx as a companion diagnostic for RET fusions as a predictor of response to selpercatinib — Europe PMC PMID:42211499},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42211499},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c89837910a36; sha256 5930039d62ca7853af18a676d8770ae5f34437a2d882c27187df3dc65dbf82a5},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42211499. Agents can read the archived copy with the MCP tool read_document.